17 apr: Europa/luk: Finanssektoren trak kraftigt op
18 apr: USA/aktier: Største stigninger i en måned
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
25 maj - 
Onsdagens aktier: Vestas med i toppen på måske-ordre ti..
25 maj - 
Sanofi vil smide Medivations bestyrelse på porten ..
25 maj - 
Aktier/middag: Novo fortsat i føretrøjen efter amerikan..
Relateret debat
26 maj - 
Kommentaren var nu positivt ment, i det du jo har til v..
26 maj - 
Husk dine faldende knive og hvad mener du nu om Lixilan..
26 maj - 
Husk dit 4% SL ;)

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
24 maj
NOVO-B
Ved godt der er en lang Novo tråd lige nedenfor, men synes Elliot fortjener en selvstændig tråd som ..
26
24 maj
NOVO-B
Tak til EliotSpitzer for opdateringen fra FDA-mødet. Imponerende arbejde og et godt ekempel på EI de..
11
24 maj
NOVO-B
Til lykke til Novo Nordisk. Der er nogle lessons to be learnt men samlet set et absolut flot resulta..
4
26 maj
NOVO-B
http://invst.ly/1s9wx   At Novo har brudt sin nedtrend, den har ligget i siden starten af 2016, er y..
3
24 maj
NOVO-B
Reaktioner på mødet   (Tue May 24, 2016 4:53pm EDT Related: HEALTH Reuters)   U.S. FDA panel recomme..
3
24 maj
NOVO-B
Jeg takker af herfra. Jeg har lovet min hustru at jeg ville bage hende et brød. 
3
24 maj
NOVO-B
Den landede på  54,97, oppe 2,25%   Jeg gik lidt tilbage i historien. Xultophy® blev godkendt i Schw..
3
24 maj
NOVO-B
Det er tydligt i den åbne FDA session at patienterne vil bare have dette produkt. Der er enighed om ..
3
24 maj
NOVO-B
En 1 år gammel oversigt over estimater på flexpenne's andel af det totale marked.   Jeg har sendt de..
3
24 maj
NOVO-B
Ja - det gør jeg. Nu er det så til hævning et stykke tid. Hustruen er gluten intolerant og derfor ha..
2

USA-vind/dir: Svært at konkurrere mod de tre store

26-05-2016 14:48:02
Det amerikanske vindmøllemarked er domineret af de tre store mølleleverandører GE, Vestas og Siemens. Men gunstige markedsudsigter i flere år frem kan få nogle ..

GE-vindboss: 3 MW-platform meget succesfuld i Europa

25-05-2016 16:20:04
GE Renewable Energys administrerende direktør for onshoremøller, Anne McEntee, udtrykker stor tilfredshed med, hvordan markedet i Europa har taget i mod selskab..

Sanofi vil smide Medivations bestyrelse på porten

25-05-2016 13:38:02
Det franske medicinalselskab Sanofi, der konkurrerer med blandt andet danske Novo Nordisk, vil have skiftet bestyrelsen i amerikanske Medivation ud for at få en..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/dir: Ordretravlhed forude på det amerikanske marked
2
Aktier/tendens: Rolig åbning mens olieprisen runder 50
3
Zealand Pharma: FDA anbefaler godkendelse af Iglarlixi
4
Pandora: Amerikansk forhandlers sammenlignelige salg falder-NY
5
USA-vind/dir: Svært at konkurrere mod de tre store

Relaterede aktiekurser

Novo Nordisk B A/S 372,10 -1,4% Fald i aktiekurs
Novo-Nordisk A/S 56,05 -0,4% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. maj 2016 02:19:54
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160526.2 - EUROWEB3 - 2016-05-27 02:19:54 - 2016-05-27 02:19:54 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x